Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...

Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Indian CDMO Aragen has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital.

Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...

Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...

Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.

Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.